Reply to Deguchi et al.

talium with macrolide and fluoroquinolone resistance in Japan [3, 10]. We created Table 1 by combining the prevalence of drug resistance–associated mutations in M. genitalium detected in 2014 with that collected from 2011 to 2013 [3]. Further increases ofM. genitalium with drug resistance–associated mutations were observed. In particular, the prevalence of M. genitalium with both macrolide resistance– and fluoroquinolone resistance–associated mutations has risen from 0% before 2013 to 16.7% in 2013 and 30.8% in 2014, indicating that multidrug-resistant M. genitalium is increasing. Before strains with clinically significant high-level resistance to all existing antibiotics emerge, the development of promising new antibiotic regimens for M. genitalium infections is imperative.